Search

Your search keyword '"DI Biagio A"' showing total 263 results

Search Constraints

Start Over You searched for: Author "DI Biagio A" Remove constraint Author: "DI Biagio A" Topic female Remove constraint Topic: female
263 results on '"DI Biagio A"'

Search Results

1. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2. Intrapartum use of zidovudine in a large cohort of pregnant women living with HIV in Italy

3. Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen

4. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

5. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

6. Mapping the human genetic architecture of COVID-19

7. Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study

8. Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort

9. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study

10. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances

11. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

12. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males

13. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

14. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

15. Viral community acquired pneumonia at the emergency department: Report from the pre COVID‐19 age

16. Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy

17. Genetic mechanisms of critical illness in COVID-19

18. Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study

19. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

20. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

21. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

22. Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy

23. Migrants and imported disease: Trends of admission in an Italian infectious disease ward during the migration crisis of 2015–2017

24. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV

25. Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2

26. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period

27. Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research

28. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

29. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

30. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

31. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study

32. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL

33. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

34. Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort

35. Factors associated with hospital admission for COVID-19 in HIV patients

36. Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience

37. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL

38. Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia

39. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity

40. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

41. Characterization of T lymphocytes in severe COVID-19 patients

42. General Practitioners as partners for a shared management of chronic HIV infection: An insight into the perspectives of Italian People Living with HIV

43. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy

44. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting

45. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014

46. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy

47. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

48. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

49. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

50. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

Catalog

Books, media, physical & digital resources